The stock market is the hypermarket of equities. You can purchase or find the ideal deals and pick quality stocks which aren’t necessarily blue-chip stocks. A couple of them are selling below $7 today. Do not ignore the limited offer since the value of the stocks could rise very well soon. These economical stocks could be the investment of a lifetime.
Stocks in biotechnology are volatile & risky. The success of biotech companies is attached to positive results of clinical studies & trials of drug candidates. BELLUS Health is devoted to developing new therapeutics for the treatment of chronic cough & other hyper-sensitization-related disorders.
The clinical-stage biopharma firm has a blockbuster drug in the making. The firm’s lead product candidate, BLU-5937, is to treat chronic cough.
In the past November, BELLUS announced the positive top-line results from the clinical phase I study of BLU-5937. The drug was proven to be well tolerated by patients and safe. With a benign side effect profile confirmed in numerous pre-clinical studies, it was revealed that the drug can be the best-in-class therapeutic for refractory chronic cough patients.
BELLUS has advanced to the phase II study for BLU-5937 in patients with refractory unsolved chronic cough. The top-line results are anticipated by mid-2020. Refractory chronic cough is a considerable unmet medical need & no presently approved treatments. For $3.09, you are invested in the future biotechnology champion.
Energy stock Encana is trading at $5.54 & is just marginally away from the 52-week low of $5.46. The forecasts of analysts should be encouraging to bargain shoppers. The price is estimated to increase between 147 percent and 279 percent in the next 12 months.
Earlier this year, the energy sector had a good run with the price even rising to $10 before falling to an all-time low. The drop made Encana super-cheap & a real giveaway considering the 1.7 percent dividend yield. However, stockholders currently aren’t likely to sell now.